Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 crossover cold challenge study of C21 in Raynaud's phenomenon secondary to systemic sclerosis
2019-003203-35Phase 2Unknown
- Sponsor
- Vicore Pharma
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of buloxibutid in Raynaud disease and systemic sclerosis (SSc) (2 arms), sponsored by Vicore Pharma. Primary endpoint: Area under the curve for rewarming after cold challenge. Status: unknown.
02
Drugs
buloxibutid
03
Conditions
Raynaud diseasesystemic sclerosis (SSc)
Beyond the preview
Go deeper on 2019-003203-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003203-35.